Letter to Shareholders, Notice of AGM & Proxy Form
Released
Released
Announcement PDF
All Registry communications to:
Automic
Group GPO
Box 5193
Sydney NSW 2001
Telephone (free call within Australia): 1300 288 664
ASX Code: RAC
22 October 2026
Racura Oncology Ltd ACN 149 318 749 (ASX: RAC or “the Company”), advises the 2026 Annual General Meeting will be
held in person at the Library Auditorium, State Library NSW, 1 Shakespeare Place, Sydney NSW 2000 on Monday, 23
November 2026 at 12.00 pm (AEDT) (Meeting). Shareholders planning to attend the Meeting in person are encouraged
to register their attendance in advance using the following link: https://events.humanitix.com/racura-oncology-agm
Notice of Meeting
The Notice of Meeting and Explanatory Memorandum (Notice) for the Meeting is available online and can be viewed and
downloaded by shareholders of the Company (Shareholders) from the Company’s website at
https://racuraoncology.com or the Company's ASX market announcements platform at www.asx.com.au (ASX: RAC).
In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws
Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy
Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice
and Proxy Form in hard copy.
Voting by Proxy
For further information on the online proxy lodgement process, or if you require a hard copy Proxy Form, please
contact the Company’s Share Registry, Automic Registry Services (Automic), at hello@automicgroup.com.au or via
phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).
Shareholder queries in relation to the Meeting
Shareholders can contact the Company Secretary with any questions prior to the meeting via email at
info@racuraoncology.com.
Copies of all Meeting related material including the Notice and the Company's Annual Report, are available to download
from the Company’s website and the Company's ASX market announcements platform. In the event it is necessary or
appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to
Shareholders via the ASX and the Company’s website.
Authorised for ASX release by the Company Secretary.
Upcoming Annual General Meeting of Shareholders
Dear Shareholder
Online
scan the QR code
below using your
smartphone
Lodge your Proxy vote online at https://singleholding.automic.com.au/login by following the below
instructions:
1. Login to the Automic website using the holding details as shown on your holding statement.
2. Click on ‘Meetings’ - ‘Vote’.
To use the online lodgment facility, Shareholders will need their holder number (Securityholder
Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding
statement.
RACURA ONCOLOGY LTD
ACN 149 318 749
NOTICE OF ANNUAL GENERAL MEETING
Notice is given that the Meeting will be held at:
TIME: 12.00 pm (AEDT)
DATE: 23 November 2026
PLACE: Library Auditorium, State Library NSW
1 Shakespeare Place
SYDNEY NSW 2000
While the 2026 AGM will be an in-person only event, a recorded copy of the
Meeting will be made available within seven days of its conclusion.
The business of the Meeting affects your shareholding and your vote is important.
This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote,
they should seek advice from their professional advisers prior to voting.
The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001
(Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at
12.00 pm (AEDT) on Saturday, 21 November 2026.
3283-08/8874846_4 2
B U S I N ES S OF TH E M EE T I N G
FINANCIAL STATEMENTS AND REPORTS
To receive and consider the annual financial report of the Company for the financial year ended
30 June 2026 together with the declaration of the Directors, the Director’s report, the Remuneration
Report and the auditor’s report.
1. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as a non-binding resolution:
“That, for the purposes of section 250R(2) of the Corporations Act and for all other
purposes, approval is given for the adoption of the Remuneration Report as
contained in the Company’s annual financial report for the financial year ended
30 June 2026.”
Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company.
2. RESOLUTION 2 – RE-ELECTION OF DR SERGE SCROFANI
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purpose of clause 15.2 of the Constitution, Listing Rule 14.5 and for all
other purposes, Dr Serge Scrofani, a Director, retires by rotation, and being eligible,
is re-elected as a Director.”
3. RESOLUTION 3 – ISSUE OF OPTIONS TO DR PETER SMITH
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.14 and
for all other purposes, approval is given for the Company to issue 163,617 Options to
Dr Peter Smith (or his nominee(s)) under the Employee Incentive Securities Plan on
the terms and conditions set out in the Explanatory Statement.”
4. RESOLUTION 4 – ISSUE OF OPTIONS TO DR DANIEL TILLETT
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.14 and
for all other purposes, approval is given for the Company to issue 259,054 Options to
Dr Daniel Tillett (or his nominee(s)) under the Employee Incentive Securities Plan on
the terms and conditions set out in the Explanatory Statement.”
5. RESOLUTION 5 – ISSUE OF OPTIONS TO DR MEGAN BALDWIN
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.14 and
for all other purposes, approval is given for the Company to issue 122,681 Options to
Dr Megan Baldwin (or her nominee(s)) under the Employee Incentive Securities Plan
on the terms and conditions set out in the Explanatory Statement.”
6. RESOLUTION 6 – ISSUE OF OPTIONS TO DR SERGE SCROFANI
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.14 and
for all other purposes, approval is given for the Company to issue 122,681 Options to
Dr Serge Scrofani (or his nominee(s)) under the Employee Incentive Securities Plan
on the terms and conditions set out in the Explanatory Statement.”
3283-08/8874846_4 3
7. RESOLUTION 7 – APPROVAL TO ISSUE OPTIONS TO DR PETER SMITH IN LIEU OF CASH BONUS
ENTITLEMENT
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is
given for the Company to issue 37,940 Options to Dr Peter Smith (or his nominee(s))
under the Employee Incentive Securities Plan on the terms and conditions set out in
the Explanatory Statement.”
8. RESOLUTION 8 – SELECTIVE SHARE BUY-BACK FROM DR DANIEL TILLETT
To consider and, if thought fit, to pass, with or without amendment, the following
Resolution as a special resolution:
“That, for the purposes of Section 257D of the Corporations Act and for all other
purposes, approval is given for the Company to selectively buy-back and cancel
89,621 Shares currently held by Dr Daniel Tillett in accordance with the terms and
conditions set out in the Explanatory Statement.”
9. RESOLUTION 9 – SELECTIVE SHARE BUY-BACK FROM MR PHILLIP LYNCH
To consider and, if thought fit, to pass, with or without amendment, the following
Resolution as a special resolution:
“That, for the purposes of Section 257D of the Corporations Act and for all other
purposes, approval is given for the Company to selectively buy-back and cancel
89,621 Shares currently held by Mr Phillip Lynch in accordance with the terms and
conditions set out in the Explanatory Statement.”
Dated: 1 October 2026
3283-08/8874846_4 4
Voting Prohibition Statements
Resolution 1 – Adoption of
Remuneration Report
In accordance with sections 250(BD)(2) and 250R, a vote on this Resolution must
not be cast:
(a) by or on behalf of a member of the Key Management Personnel,
details of whose remuneration are included in the Remuneration
Report or a Closely Related Party of such a member, regardless of the
capacity in which the vote is cast; or
(b) as a proxy by a member of the Key Management Personnel at the
date of the Meeting, or their Closely Related Parties.
However, a person (the voter) described above may cast a vote on this
Resolution as a proxy if the vote is not cast on behalf of a person described
above and either:
(a) the voter is appointed as a proxy by writing that specifies the way the
proxy is to vote on this Resolution; or
(b) the voter is the Chair and the appointment of the Chair as proxy:
(i) does not specify the way the proxy is to vote on this
Resolution; and
(ii) expressly authorises the Chair to exercise the proxy even
though this Resolution is connected directly or indirectly
with the remuneration of a member of the Key
Management Personnel.
Resolution 3 – Issue of Options to
Dr Peter Smith
In accordance with section 224 of the Corporations Act, a vote on this Resolution
must not be cast (in any capacity) by or on behalf of a related party of the
Company to whom the Resolution would permit a financial benefit to be given,
or an associate of such a related party (Resolution 3 Excluded Party). However,
the above prohibition does not apply if the vote is cast by a person as proxy
appointed by writing that specifies how the proxy is to vote on the Resolution
and it is not cast on behalf of a Resolution 3 Excluded Party.
In accordance with section 250BD of the Corporations Act, a person appointed
as a proxy must not vote, on the basis of that appointment, on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
Provided the Chair is not a Resolution 3 Excluded Party, the above prohibition
does not apply if:
(a) the proxy is the Chair; and
(b) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
Resolution 4 – Issue of Options to
Dr Daniel Tillett
In accordance with section 224 of the Corporations Act, a vote on this Resolution
must not be cast (in any capacity) by or on behalf of a related party of the
Company to whom the Resolution would permit a financial benefit to be given,
or an associate of such a related party (Resolution 4 Excluded Party). However,
the above prohibition does not apply if the vote is cast by a person as proxy
appointed by writing that specifies how the proxy is to vote on the Resolution
and it is not cast on behalf of a Resolution 4 Excluded Party.
In accordance with section 250BD of the Corporations Act, a person appointed
as a proxy must not vote, on the basis of that appointment, on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
Provided the Chair is not a Resolution 4 Excluded Party, the above prohibition
does not apply if:
(a) the proxy is the Chair; and
(b) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
3283-08/8874846_4 5
Resolution 5 – Issue of Options to
Dr Megan Baldwin
In accordance with section 224 of the Corporations Act, a vote on this Resolution
must not be cast (in any capacity) by or on behalf of a related party of the
Company to whom the Resolution would permit a financial benefit to be given,
or an associate of such a related party (Resolution 5 Excluded Party). However,
the above prohibition does not apply if the vote is cast by a person as proxy
appointed by writing that specifies how the proxy is to vote on the Resolution
and it is not cast on behalf of a Resolution 5 Excluded Party.
In accordance with section 250BD of the Corporations Act, a person appointed
as a proxy must not vote, on the basis of that appointment, on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
Provided the Chair is not a Resolution 5 Excluded Party, the above prohibition
does not apply if:
(c) the proxy is the Chair; and
(d) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
Resolution 6 – Issue of Options to
Dr Serge Scrofani
In accordance with section 224 of the Corporations Act, a vote on this Resolution
must not be cast (in any capacity) by or on behalf of a related party of the
Company to whom the Resolution would permit a financial benefit to be given,
or an associate of such a related party (Resolution 6 Excluded Party). However,
the above prohibition does not apply if the vote is cast by a person as proxy
appointed by writing that specifies how the proxy is to vote on the Resolution
and it is not cast on behalf of a Resolution 6 Excluded Party.
In accordance with section 250BD of the Corporations Act, a person appointed
as a proxy must not vote, on the basis of that appointment, on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
Provided the Chair is not a Resolution 6 Excluded Party, the above prohibition
does not apply if:
(c) the proxy is the Chair; and
(d) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
Resolution 7 – Approval to Issue
Options to Dr Peter Smith In Lieu
of Cash Bonus Entitlement
A person appointed as a proxy must not vote, on the basis of that appointment,
on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
However, the above prohibition does not apply if:
(c) the proxy is the Chair; and
(d) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
Resolution 8 – Selective Share
Buy-Back from Dr Daniel Tillett
In accordance with section 257D(1)(a) of the Corporations Act, the Company
will disregard any votes cast in favour of the resolution by or on behalf of Dr
Daniel Tillett (or his nominee(s)) and of his associates.
Resolution 9 – Selective Share
Buy-Back from Mr Phillip Lynch
In accordance with section 257D(1)(a) of the Corporations Act, the Company
will disregard any votes cast in favour of the resolution by or on behalf of Mr Phillip
Lynch (or his nominee(s)) and of his associates.
3283-08/8874846_4 6
Voting Exclusion Statements
In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the
Resolutions set out below by or on behalf of the following persons:
Resolution 3 – Issue of Options to
Dr Peter Smith
Dr Peter Smith (or his nominee(s)) or any other person referred to in Listing Rule
10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive
scheme in question or an associate of that person or those persons.
Resolution 4 – Issue of Options to
Dr Daniel Tillett
Dr Daniel Tillett (or his nominee(s)) or any other person referred to in Listing Rule
10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive
scheme in question or an associate of that person or those persons.
Resolution 5 – Issue of Options to
Dr Megan Baldwin
Dr Megan Baldwin (or her nominee(s)) or any other person referred to in Listing
Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee
incentive scheme in question or an associate of that person or those persons.
Resolution 6 – Issue of Options to
Dr Serge Scrofani
Dr Serge Scrofani (or his nominee(s)) or any other person referred to in Listing Rule
10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive
scheme in question or an associate of that person or those persons.
Resolution 7 – Approval to Issue
Options to Dr Peter Smith In Lieu
of Cash Bonus Entitlement
Dr Peter Smith (or his nominee(s)) and any other person referred to in Listing Rule
10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive
scheme in question or an associate of that person or those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with the directions given to the proxy or attorney to vote on the Resolution in
that way; or
(b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with a direction given to the Chair to vote on the Resolution as the Chair
decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf
of a beneficiary provided the following conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary is
not excluded from voting, and is not an associate of a person excluded from
voting, on the Resolution; and
(ii) the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
3283-08/8874846_4 7
Voting by proxy
To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in
accordance with the instructions set out on the Proxy Form.
In accordance with section 249L of the Corporations Act, Shareholders are advised that:
• each Shareholder has a right to appoint a proxy;
• the proxy need not be a Shareholder of the Company; and
• a Shareholder who is entitled to cast two or more votes may appoint two proxies and may
specify the proportion or number of votes each proxy is appointed to exercise. If the
Shareholder appoints two proxies and the appointment does not specify the proportion or
number of the member’s votes, then in accordance with section 249X(3) of the
Corporations Act, each proxy may exercise one-half of the votes.
Shareholders and their proxies should be aware that:
• if proxy holders vote, they must cast all directed proxies as directed; and
• any directed proxies which are not voted will automatically default to the Chair, who must
vote the proxies as directed.
Voting in person
To vote in person, attend the Meeting at the time, date and place set out above.
You may still attend the Meeting and vote in person even if you have appointed a proxy. If you
have previously submitted a Proxy Form, your attendance will not revoke your proxy appointment
unless you actually vote at the Meeting for which the proxy is proposed to be used, in which case,
the proxy’s appointment is deemed to be revoked with respect to voting on that Resolution.
Please bring your personalised Proxy Form with you as it will help you to register your attendance at
the Meeting. If you do not bring your Proxy Form with you, you can still attend the Meeting but
representatives from Automic Share Registry will need to verify your identity. You can register from
11.30 am AEDT on the day of the Meeting.
Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company
Secretary on +61 409 328 199.
3283-08/8874846_4 8
E X PL A N A T O R Y S T A T EM E N T
This Explanatory Statement has been prepared to provide information which the Directors believe
to be material to Shareholders in deciding whether or not to pass the Resolutions.
1. FINANCIAL STATEMENTS AND REPORTS
In accordance with the Corporations Act, the business of the Meeting will include receipt
and consideration of the annual financial report of the Company for the financial year
ended 30 June 2026 together with the declaration of the Directors, the Directors’ report,
the Remuneration Report and the auditor’s report.
The Company will not provide a hard copy of the Company’s annual financial report to
Shareholders unless specifically requested to do so. The Company’s annual financial report
is available on its website at www.racuraoncology.com.
2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
2.1 General
The Corporations Act requires that at a listed company’s annual general meeting, a
resolution that the remuneration report to be adopted must be put to the shareholders.
However, such a resolution is advisory only and does not bind the company or the directors
of the company.
The remuneration report sets out the company’s remuneration arrangements for the
directors and senior management of the company. The remuneration report is part of the
directors’ report contained in the annual financial report of the company for a financial
year.
The chair of the meeting must allow a reasonable opportunity for its shareholders to ask
questions about or make comments on the remuneration report at the annual general
meeting.
2.2 Voting consequences
A company is required to put to its shareholders a resolution proposing the calling of
another meeting of shareholders to consider the appointment of directors of the company
(Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast
on a remuneration report resolution are voted against adoption of the remuneration report
and at the first of those annual general meetings a Spill Resolution was not put to vote. If
required, the Spill Resolution must be put to vote at the second of those annual general
meetings.
If more than 50% of votes cast are in favour of the Spill Resolution, the company must
convene a shareholder meeting (Spill Meeting) within 90 days of the second annual
general meeting.
All of the directors of the company who were in office when the directors' report (as
included in the company’s annual financial report for the most recent financial year) was
approved, other than the managing director of the company, will cease to hold office
immediately before the end of the Spill Meeting but may stand for re-election at the Spill
Meeting.
Following the Spill Meeting those persons whose election or re-election as directors of the
company is approved will be the directors of the company.
2.3 Previous voting results
At the Company’s previous annual general meeting the votes cast against the
remuneration report considered at that annual general meeting were less than 25%.
Accordingly, the Spill Resolution is not relevant for this Meeting.
3283-08/8874846_4 9
3. RESOLUTION 2 – RE-ELECTION OF DR SERGE SCROFANI
3.1 General
Listing Rule 14.5 provides that an entity which has directors must hold an election of
directors at each annual general meeting.
The Constitution sets out the requirements for determining which Directors are to retire by
rotation at an annual general meeting.
Dr Serge Scrofani, who has held office without re-election since 25 November 2024 and
being eligible retires by rotation and seeks re-election.
Further information in relation to Dr Scrofani is set out below.
Qualifications,
experience and
other material
directorships
Dr Scrofani has more than 29 years' experience in the healthcare
sector, working in global roles across research and strategy, and
corporate and business development.
After obtaining his PhD in Structural Biology from La Trobe
University, Dr Scrofani undertook postdoctoral research studies at
The University of Melbourne and completed a Fulbright
Postdoctoral Fellowship at The Scripps Research Institute, La Jolla,
California. He also holds an MBA from Melbourne Business School.
He served as Vice President of Strategy & Corporate
Development at CSL Limited for 13 years, where he played a
pivotal role in multiple strategic initiatives and major M&A
transactions.
Dr Scrofani is currently Chief Executive Officer and Managing
Director of private investment firm FinCap Group Holdings Pty Ltd.
He is also a Board Member of the Burnet Institute and The Centre
for Eye Research.
Term of office Dr Scrofani has served as a Director since 1 September 2024 and
was last elected on 25 November 2024.
Independence If re-elected, the Board considers that Dr Scrofani will be an
independent Director.
Board
recommendation
Having received an acknowledgement from Dr Scrofani that he
will have sufficient time to fulfil his responsibilities as a Director and
having reviewed the performance of Dr Scrofani since his
appointment to the Board and the skills, knowledge, experience
and capabilities required by the Board, the Directors (other than
Dr Scrofani) recommend that Shareholders vote in favour of this
Resolution.
3.2 Technical information required by Listing Rule 14.1A
If this Resolution is passed, Dr Scrofani will be re-elected to the Board as an Independent
Non-Executive Director.
If this Resolution is not passed, Dr Scrofani will not continue in his role as an Independent
Non-Executive Director. The Company may seek nominations or otherwise identify suitably
qualified candidates to join the Company. As an additional consequence, this may
detract from the Board and Company’s ability to execute on its strategic vision.
4. RESOLUTIONS 3 TO 6 – ISSUE OF OPTIONS TO DIRECTORS
4.1 General
These Resolutions seek Shareholder approval for the purposes of Chapter 2E of the
Corporations Act and Listing Rule 10.14 for the issue of an aggregate of 668,033 Options to
Dr Peter Smith, Dr Daniel Tillett, Dr Megan Baldwin and Dr Scrofani (or their nominee(s))
pursuant to the Employee Incentive Securities Plan (Plan) on the terms and conditions set
out below.
3283-08/8874846_4 10
Further details in respect of the Options proposed to be issued are set out in the table
below.
QUANTUM RECIPIENT RESOLUTION EXERCISE PRICE EXPIRY DATE
163,617 Dr Smith 3 $3.05 30 June 2030
259,054 Dr Tillett 4 $3.05 30 June 2030
122,681 Dr Baldwin 5 $3.05 30 June 2030
122,681 Dr Scrofani 6 $3.05 30 June 2030
4.2 Director Recommendation
Each Director has a material personal interest in the outcome of these Resolutions on the
basis that all of the Directors (or their nominee(s)) are to be issued Securities should these
Resolutions be passed. For this reason, the Directors do not believe that it is appropriate to
make a recommendation on these Resolutions.
4.3 Chapter 2E of the Corporations Act
Chapter 2E of the Corporations Act requires that for a public company, or an entity that
the public company controls, to give a financial benefit to a related party of the public
company, the public company or entity must:
(a) obtain the approval of the public company’s members in the manner set out in
sections 217 to 227 of the Corporations Act; and
(b) give the benefit within 15 months following such approval,
unless the giving of the financial benefit falls within an exception set out in sections 210 to
216 of the Corporations Act.
The issue constitutes giving a financial benefit and each of the proposed recipients is a
related party of the Company by virtue of being a Director.
As Securities are proposed to be issued to all of the Directors, the Directors are unable to
form a quorum to consider whether one of the exceptions set out in sections 210 to 216 of
the Corporations Act applies to the issue. Accordingly, Shareholder approval for the issue
is sought in accordance with Chapter 2E of the Corporations Act.
4.4 Listing Rule 10.14
Listing Rule 10.14 provides that an entity must not permit any of the following persons to
acquire equity securities under an employee incentive scheme without the approval of
the holders of its ordinary securities:
10.14.1 a director of the entity;
10.14.2 an associate of a director of the entity; or
10.14.3 a person whose relationship with the entity or a person referred to in Listing
Rules 10.14.1 to 10.14.2 is such that, in ASX’s opinion, the acquisition should be
approved by security holders.
The issue falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders
under Listing Rule 10.14.
4.5 Technical information required by Listing Rule 14.1A
If these Resolutions are passed, the Company will be able to proceed with the issue within
15 months after the date of the Meeting (or such later date as permitted by any ASX waiver
or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required
for the issue (because approval is being obtained under Listing Rule 10.14), the issue will
not use up any of the Company’s 15% annual placement capacity.
If these Resolutions are not passed, the Company will not be able to proceed with the issue
of the Options under the Plan, and the Company may have to find alternative methods to
3283-08/8874846_4 11
incentivise and remunerate the Directors, some of which may not be as financially
preferred for the Company as the issue of the Options.
4.6 Technical information required by Listing Rule 10.15 and section 219
Share your feedback
Discover